Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a leader in innovative therapeutics for life-threatening and life-debilitating diseases, announced that the Company has received FDA approval to begin Phase II trials for Serdaxin™, for the treatment of major depressive disorders (MDD). This trial represents the third Phase II study currently in progress at Rexahn Pharmaceuticals.
Popularity: unranked [?]
Related posts:
- Rexahn Pharmaceuticals, Inc. Initiates Clinical Trial Of Serdaxin(TM) To Treat Depression
- Rexahn Achieves 50% Enrollment Milestone In Serdaxin™ Phase IIa Clinical Trial For Depression
- Rexahn Pharmaceuticals, Inc. Initiates Clinical Trial Of SerdaxinTM To Treat Depression
- Rexahn Reports Positive Top-line Phase IIa Data For SerdaxinTM In Patients With Major Depressive Disorder (MDD)
- DOV Pharmaceutical, Inc. Initiates Phase II Clinical Trial In Patients With Major Depressive Disorder
Comments
No Responses to “Rexahn Pharmaceuticals Receives FDA Approval To Initiate Phase II Trial For Serdaxin In Patients With Major Depressive Disorders”